“showed a trend”

Median I-FABP levels in the negative laparotomy group (301 pg/mL) showed a trend to significance compared to the positive laparotomy group (1,177 pg/mL, p = 0.05).

Echocardiography With regard to EF and FS, both showed a trend toward gradual decline in the diabetic rats over the 12 weeks, with significant reductions ( P < 0.05) after diabetes was induced and significant increase( P < 0.05) in Fgl2–RNAi gene silencing group compared with diabetes group (DM), diabetic empty vector group (DM-GFP; Table 2 ).

MiR-21 showed a trend of upregulation (>1.6-fold, p<0.05) only at 12 h post-OGD.

With respect to the lipid profile, although total cholesterol and high-density lipoprotein (HDL) levels showed a trend toward variation between the groups, these differences did not reach statistical significance ( P > 0.05) [ Table 3 ].

Compared to those of HC, the motor nerve excitability of the patients with N 2 O abuse showed a trend of decreased peak response (7.08 ± 0.87 mV, p = 0.05), increased latency (7.09 ± 0.28 ms, p < 0.01), increased superexcitability (−32.95 ± 1.74%, p < 0.05), and decreased TE accommodation to depolarizing current [TEd [40–60 ms] 56.53 ± 0.70%, p < 0.05].

The features that showed a trend and passed both the linear mixed-effect model and the t test ( p < 0.05) were selected to be used to build a model to predict treatment response as early as possible during treatment.

Reference men with b2/b4 duplication compared to subjects with no AZFc rearrangements showed a trend for lower follicle-stimulating hormone (FSH) (median 2.3 [5–95% range 1.4–7.5] vs 3.2 [1.3–7.1] IU/l; p<0.05) and luteinizing hormone (LH) (3.1 [1.7–5.0] vs 3.8 (1.7–7.2) IU/l; p<0.05).

Among the treatment groups, both the P-T and PM-T groups significantly lowered MDA levels (P<0.05), and although the M-T group also showed a trend toward reducing MDA, the difference was not statistically significant compared with the Mod-T group (P>0.05).

With regards to FEV1, the combined cell-dose groups showed a trend of improvement at 3 months (0.12 L [95% CI: 0.0007, 0.24], p = .05) and 6 months (0.09 L [95% CI: −0.06, 0.24], p = .23).

Additionally, Cyp17a1 showed a trend toward higher expression ( p = 0.05).

Tested in the same tissue samples, 3-HK production from both precursors showed a trend to increase as a result of the NAC treatment, but the differences from saline-treated controls did not attain statistical significance (* p > 0.05; Mann–Whitney test) ( Figure 3 B). 3.4.

GSH levels showed a trend of gradual increase, peaked in the DCP30 group ( p < 0.05), and decreased in the DCP40 and DCP50 groups ( p > 0.05).

Patients with a primary site in the small intestine showed a trend toward T3–T4 (42.2%), whereas primary sites in the colorectum had a higher proportion of T1–T2 (40.0%, p = 0.050).

End-effector robots (n = 6) showed significant improvement (SMD = 0.30, 95% CI: 0.03–0.58, p = 0.030, I 2 = 0%), while exoskeletons showed a trend (SMD = 0.72, 95% CI: −0.01 to 1.45, p = 0.050, I 2 = 78%) ( Figure 3 B). 3.4.3.

The secondary outcomes also showed a trend toward benefit, including body mass index (BMI) and waist-to-hip ratio ( p < 0.05).

To explore which patients could have potential DFS benefit from RT, we also performed subgroup analyses and observed that patients with PI as well as those without resection for primary tumor showed a trend to benefit from RT, but with a P value > 0.05.

A one-way ANOVA showed a trend toward significant differences among the RTLE, LTLE, and healthy control groups for hippocampal activation ARs, F (2,26) = 3.37, p = 0.05.

The study, which was completed in 2010 (27 patients received minocycline and 25 received placebo), showed a trend toward improved motor scores in incomplete cervical SCI cases in the absence of any serious adverse effects ( P = 0.05) but no improvement in thoracic SCI 49 (ClinicalTrials.gov identifier NCT00559494 ).

Among the covariates, non-contained disc morphology showed a trend toward lower odds of success (adjusted OR = 0.51; p = 0.05).

Meanwhile, the Anti-CTLA4 group showed a trend of rapid tumor growth after eight days of treatment, indicating that the therapeutic effect of Anti-CTLA4 alone was not satisfactory ( P > 0.05), while the combination treatment with X-PDT or RT could achieve better tumor suppression effect due to the immune system activation by X-PDT.

Likewise, the increased occurrence of L2 among patients with PSC was not found among patients with other IMIDs; in contrast, patients with ankylosing spondylitis showed a trend toward a lower occurrence of colonic disease [RR = 0.75 (95% CI 0.56–1.00), p = 0.05, I 2 = 0%] ( Figure 2 ).

Although the glaucoma group showed a trend towards poorer VRQoL on several scales, no statistically significant difference was found among the four ocular condition groups (all p > 0.05).

Later age of symptom onset (70+ years) was associated with lower odds of genetic testing completion (OR 0.23; 95% CI 0.12–0.43; P < 0.001) compared to the reference group (10–19 years), while early symptom onset (0–9 years) showed a trend toward higher odds of genetic testing completion that approached but did not reach statistical significance (OR 1.53; 95% CI 1–2.37; P = 0.05).

While E2 levels in the Ctr-T group showed a trend toward lower levels than the Sham group, this difference was not statistically significant ( P > 0.05).

Compared with the control group, the MM28 group showed a trend toward reduced serum MDA content ( p > 0.05) and increased activities of SOD and GSH-PX.